IMMURON LTD-SPON ADR
IMRNNASDAQUS Equity
$932.63▲ $6.34 (+0.68%)
Simulated price1h—
24h▲ 0.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$192.91B
Mid Cap
📈Revenue Growth (YoY)
+14.3%
Healthy
📊Gross Margin
63.7%
High
💵FCF Margin
—
⚖️P/S Ratio
1.4x
Cheap
Otter Score
54
Weak
No chart data available for IMRN.
Trading Snapshot
- Day Range
- $925.08 – $937.59
- 52-Week Range
- —
- Volume
- $2.31B
- Avg Volume
- $1.80B
- Shares Outstanding
- 322.9M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $25.38B
- Last Q Revenue
- $6.48B
- P/E Ratio
- —
- P/S Ratio
- 1.4x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own IMRN
- ✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$25.38B▼ −6.8% YoY
Gross Margin (TTM)
31.2%▲ +1.2% YoY
Operating Income (TTM)
$5.10B▼ −6.8% YoY
Free Cash Flow (TTM)
$1.07B▼ −6.8% YoY
About IMMURON LTD-SPON ADR
A company profile for IMMURON LTD-SPON ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Price Target
ⓘAverage Target
$1,117.58
▲ +19.8% Upside
High Target$1,338.00
Low Target$913.82
Based on 29 analysts
Latest News & Updates
🚀
Barron’s·2h ago
IMMURON LTD-SPON ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift IMRN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
IMMURON LTD-SPON ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.